NCT04969276View on ClinicalTrials.gov

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

February 8, 2022

Study Completion Date

February 8, 2022

Conditions
Influenza ImmunizationHealthy Volunteers
Interventions
BIOLOGICAL

Quadrivalent Inactivated Influenza High Dose

Sterile suspension for injection in a pre-filled syringe Intramuscular injection

BIOLOGICAL

COVID-19 mRNA Vaccine (nucleoside modified)

Sterile suspension (white to off-white) in multidose vial Intramuscular injection

Trial Locations (6)

61614

Investigational Site Number :8400001, Peoria

78705

Investigational Site Number :8400002, Austin

80112

Investigational Site Number :8400005, Centennial

85306

Investigational Site Number :8400003, Glendale

92083

Investigational Site Number :8400004, Vista

92108

Investigational Site Number :8400006, San Diego

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04969276 - Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine | Biotech Hunter | Biotech Hunter